Work

Significant antitumor activity for low-dose ipilimumab (IPI) with pembrolizumab (PEMBRO) immediately following progression on PD1 Ab in melanoma (MEL) in a phase II trial.

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.10004

Authors: Daniel Olson, Jason J. Luke, Andrew Stewart Poklepovic, Madhuri Bajaj, Emily Higgs, Timothy C. Carll, Brian Labadie, Thomas Krausz, Yuanyuan Zha, Theodore Karrison, Jose Lutzky, Sigrun Hallmeyer, Bruce Brockstein, Vernon K. Sondak, Zeynep Eroglu, Thomas Gajewski, Nikhil I. Khushalani

Institutions: University of Chicago, University of Chicago Medicine Comprehensive Cancer Center, University of Pittsburgh, UPMC Hillman Cancer Center, VCU Massey Comprehensive Cancer Center, Illinois CancerCare, University of Chicago Medical Center, Mount Sinai Medical Center, Oncology Specialists, Endeavor Health, Moffitt Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3029560938

Cites:

Cited by: 25

Related to: 10